PCSK9(D374T) [Biotinylated]-LDLR Binding Assay Kit
The PCSK9(D374T) [Biotinylated]-LDLR Binding Assay Kit is designed for screening and profiling purposes. This assay takes advantage of the high sensitivity of detection of biotin-labeled PCSK9(D374T) by streptavidin-HRP. Only a few steps are required for the assay. First, LDLR ectodomain is coated on a 384-well plate. Next, PCSK9(D374T) is incubated with LDLR on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.
Need us to run inhibitor screens or profile your compounds against PCSK9(D374T)-LDLR? Check out our PCSK9 Screening Services.
- PBS buffer (Phosphate Buffer Saline)
- Luminometer or microplate reader capable of reading chemiluminescence
- Rotating or rocker platform
96 reactions
Catalog # | Name | Amount | Storage |
71211 | PCSK9(D374T), Biotin-Labeled* | 10 µg | -80°C |
71205 | LDLR* | 10 µg | -20°C |
79742 | Streptavidin-HRP | 10 µl | -20°C |
33298 | 3x PL-01 Assay Buffer | 50 ml | -20°C |
79728 | Blocking Buffer 2 | 50 ml | +4°C |
79670 | ELISA ECL Substrates A and B (2 components) | 6 ml each | Room Temp. |
79699 | 96-well plate, white | 1 | +4°C |
* The concentration of protein is lot-specific and will be indicated on the tube containing the protein
384 reactions
Catalog # | Name | Amount | Storage | |
71211 | PCSK9(D374T), Biotin-Labeled* | 2 x 10 µg | -80°C | Avoid multiple freeze/ thaw cycles |
71205 | LDLR, FLAG-Tag* | 2 x 10 µg | -80°C | |
79742 | Streptavidin-HRP | 2 x 10 µl | 4°C | |
33298 | 3x PL-01 Assay Buffer | 2 x 50 ml | -20°C | |
79728 | Blocking Buffer 2 | 2 x 50 ml | 4°C | |
79670 | ELISA ECL Substrate A (translucent bottle) | 2 x 6 ml | Room Temp | |
ELISA ECL Substrate B (brown bottle) | 2 x 6 ml | Room Temp | ||
78188 | 384-well plate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
PCSK9 (Proprotein convertase subtilisin/kexin type 9) functions as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) by binding to the LDLR ectodomain. The D374T mutation is associated with hypercholesterolemia; this form of PCSK9 is more potent at decreasing LDL uptake than wild-type PCSK9, most likely by increasing the binding affinity of PCSK9 for the LDLR.
1. Chan, J.C. et al. (2009). Natl Acad. Sci. USA, 106, 9820-9825.
2. Liang, H., et al. (2012) Pharmacol. Exp. Ther. 340, 2289-236.